Google+ Followers

mercredi 3 avril 2013

Niacin for dyslipidemia: end of the story!


  • Excess diabetic complications: 3.7% (P<0 .0001="" li="">
  • Excess new onset diabetes: 1.8% (P<0.0001)
  • Excess infection: 1.4% (P<0.0001)
  • Excess gastrointestinal complications: 1% (P<0.0001)
  • Excess bleeding (GI and intracranial): 0.7% (P<0.0002)
Armitage J, et al "HPS2-THRIVE: Randomized placebo-controlled trial of ER Niacin and laropriprant in 25,673 patients with pre-existing cardiovascular disease" ACC 2013.

Aucun commentaire: